<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>C1 inhibitor, concentrate from human plasma: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">C1 inhibitor, concentrate from human plasma: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">C1 inhibitor, concentrate from human plasma: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12114" href="/d/html/12114.html" rel="external">see "C1 inhibitor, concentrate from human plasma: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="16458" href="/d/html/16458.html" rel="external">see "C1 inhibitor, concentrate from human plasma: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F6759053"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Berinert;</li>
<li>Cinryze;</li>
<li>Haegarda</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868981"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Berinert;</li>
<li>Cinryze;</li>
<li>Haegarda</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F6761341"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Blood Product Derivative;</li>
<li>
                        C1 Esterase Inhibitor;</li>
<li>
                        Complement Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F6764794"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6b86c2d6-a775-4c42-a576-933293fd2ea9">Hereditary angioedema attacks, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hereditary angioedema attacks, prophylaxis:</b>
<b>Note:</b> Have on-demand therapy available for all patients (breakthrough attacks may occur) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35497649']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35497649'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Guideline recommendations: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Short-term/pre-procedural prophylaxis </i>(off-label use):</b> Berinert or Cinryze: <b>IV:</b> 20 units/kg <b>or</b> 1,000 units as close as possible to the start of the procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35497649']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35497649'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Long-term prophylaxis </i></b>
<b>(off-label dose):</b> Haegarda: <b>SUBQ:</b> 40 or 60 units/kg twice weekly; adjust dose based on patient response. <b>Note:</b> SUBQ administration may provide more convenient administration as well as improved steady state plasma concentrations (compared to IV administration) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28328347','lexi-content-ref-35497649']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28328347','lexi-content-ref-35497649'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Manufacturer's labeling:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Long-term prophylaxis:</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Cinryze: IV:</b> 1,000 units every 3 to 4 days; if response is not adequate, doses up to 2,000 units (not exceeding 80 units/kg) every 3 or 4 days may be considered based on individual patient response. <b>Note:</b> Prior to March 2022, the manufacturer's labeling stated that if response was not adequate, doses up to 2,500 units every 3 or 4 days could be considered; however, internal standardization of international units made them reduce this to 2,000 units.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Haegarda:</b>
<b>SUBQ:</b> 60 units/kg every 3 or 4 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e6fdac7f-1466-435d-8ceb-b7b28141de63">Hereditary angioedema attacks, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hereditary angioedema attacks, treatment (Berinert [labeled use]; Cinryze [off-label use]): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>To minimize morbidity and mortality, should be self-administered (or administered by a caregiver) at the onset of an attack whenever possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32898710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32898710'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Berinert:</i>
<b> IV:</b> 20 units/kg once as soon as possible after symptom onset. Some experts recommend rounding up the dose to utilize a full vial (500 units/vial) as follows (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19767078','lexi-content-ref-27286778','lexi-content-ref-26304015','lexi-content-ref-Zuraw.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19767078','lexi-content-ref-27286778','lexi-content-ref-26304015','lexi-content-ref-Zuraw.1','lexi-content-ref-Manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Weight ≤50 kg: 1,000 units.</p>
<p style="text-indent:-2em;margin-left:6em;">Weight &gt;50 kg and ≤75 kg: 1,500 units.</p>
<p style="text-indent:-2em;margin-left:6em;">Weight &gt;75 kg and ≤100 kg: 2,000 units.</p>
<p style="text-indent:-2em;margin-left:6em;">Weight &gt;100 kg: 2,500 units; single doses up to 3,500 units have been reported.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Repeat dosing</i>
<i>:</i> A clinical response is usually observed within ~1 to 2 hours of the initial dose; after ~1 to 2 hours, a second dose may be given if symptoms worsen, but this is rarely needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19767078','lexi-content-ref-27286778','lexi-content-ref-26304015','lexi-content-ref-Zuraw.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19767078','lexi-content-ref-27286778','lexi-content-ref-26304015','lexi-content-ref-Zuraw.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cinryze</i>: <b>IV:</b> 1,000 units once as soon as possible after symptom onset; if symptoms do not resolve or show improvement after 1 hour, administer a second dose of 1,000 units (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20818886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20818886'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991877"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50989204"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F6764795"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F6764793"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="16458" href="/d/html/16458.html" rel="external">see "C1 inhibitor, concentrate from human plasma: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Products are not interchangeable and product-specific dosing is necessary; use caution.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6b86c2d6-a775-4c42-a576-933293fd2ea9">Hereditary angioedema attacks, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hereditary angioedema (HAE) attacks, prophylaxis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Short-term prophylaxis: </i> Limited data available: <b>Note:</b> If used for preprocedural prophylaxis, administer as close as possible to the beginning of the procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29318628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29318628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Berinert: Children and Adolescents: IV: 15 to 30 units/<b>kg</b>; administer within 6 hours or immediately prior to significant medical, surgical, or dental procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33980333','lexi-content-ref-27503784','lexi-content-ref-28781749','lexi-content-ref-32898710','lexi-content-ref-29318628','lexi-content-ref-Berinert.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33980333','lexi-content-ref-27503784','lexi-content-ref-28781749','lexi-content-ref-32898710','lexi-content-ref-29318628','lexi-content-ref-Berinert.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Cinryze:</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥2 to &lt;12 years and weighing 10 to 25 kg: IV: 500 units; administer within 24 hours of the procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cinryze.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cinryze.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥2 to &lt;12 years and weighing &gt;25 kg and Adolescents: IV: 1,000 units; administer within 24 hours of the procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cinryze.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cinryze.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Long-term prophylaxis</i>: <b>Note:</b> For long-term prophylaxis, C1 inhibitor therapy is considered first line and subcutaneous administration may provide greater convenience as well as improved steady-state plasma concentrations (compared to IV administration) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32898710','lexi-content-ref-29318628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32898710','lexi-content-ref-29318628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Cinryze:</p>
<p style="text-indent:-2em;margin-left:8em;">Children 6 to 11 years: IV: 500 units every 3 to 4 days; if inadequate response, may increase dose to 1,000 units every 3 to 4 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32898710','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32898710','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: IV: 1,000 units every 3 to 4 days; if an adequate response is not achieved, doses up to 2,000 units (≤80 units/<b>kg</b>/dose) every 3 to 4 days may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32898710','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32898710','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note:</b> Prior to March 2022, the manufacturer's labeling stated that if response was not adequate, doses up to 2,500 units every 3 or 4 days could be considered; however, internal restandardization of international units by the manufacturer equated to the reduced dose of 2,000 units.</p>
<p style="text-indent:-2em;margin-left:6em;">Haegarda: Children ≥6 years and Adolescents: SUBQ: 60 units/<b>kg</b>/dose every 3 or 4 days; in trials, the youngest patient recruited was 8 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32042283','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32042283','lexi-content-ref-Manu.1'])">Ref</a></span>). A lower dose of 40 units/<b>kg</b>/dose has been studied; however, it appears to have a lower response rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32042283','lexi-content-ref-28328347']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32042283','lexi-content-ref-28328347'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e6fdac7f-1466-435d-8ceb-b7b28141de63">Hereditary angioedema attacks, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hereditary angioedema (HAE) attacks (abdominal, facial or laryngeal), treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Berinert: Limited data in ages &lt;5 years: Children and Adolescents: IV: 20 units/<b>kg </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32898710','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32898710','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Cinryze: Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 years:</p>
<p style="text-indent:-2em;margin-left:8em;">10 to 25 kg: IV: 500 units; may repeat dose in 1 hour if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cinryze.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cinryze.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;25 kg: IV: 1,000 units; may repeat dose in 1 hour if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cinryze.2','lexi-content-ref-23312695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cinryze.2','lexi-content-ref-23312695'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents IV: 1,000 units; may repeat dose in 1 hour if needed; may repeat sooner if treating laryngeal attacks or if initiation of treatment has been delayed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cinryze.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cinryze.2'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51090231"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51090232"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F6764784"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatological: Skin rash (21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (35%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (19%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (≥5%), dysgeusia (5%), vomiting (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (&gt;5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, arterial thromboembolism, chills, erythema at injection site, infusion site reaction, injection site pain, shock, thrombosis, venous thromboembolism</p></div>
<div class="block coi drugH1Div" id="F6764780"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">History of anaphylactic or life-threatening hypersensitivity reactions to C1 inhibitor (human) or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F6764781"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Severe hypersensitivity reactions (eg, urticaria, hives, tightness of the chest, wheezing, hypotension, anaphylaxis) may occur during or after administration. Signs/symptoms of hypersensitivity reactions may be similar to the attacks associated with hereditary angioedema, therefore, consideration should be given to treatment methods. In the event of acute or severe hypersensitivity reactions, discontinue treatment immediately.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombotic events: Serious arterial and venous thromboembolic events have been reported at recommended intravenous doses and when used off-label at doses higher than recommended. Risk factors may include the presence of an indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives or certain androgens, morbid obesity, and immobility. Consider potential risk of thrombosis with use, and closely monitor patients with preexisting risks for thrombotic events.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Human plasma: Product of human plasma; may potentially contain infectious agents (eg, viruses, the variant Creutzfeldt-Jakob disease [vCJD] agent and, theoretically, the Creutzfeldt-Jakob disease [CJD] agent) that could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Self-administration: Due to the potential for airway obstruction, patients suffering from an acute laryngeal hereditary angioedema (HAE) attack and self-administering should be informed to immediately seek medical attention following treatment.</p></div>
<div class="block foc drugH1Div" id="F6764799"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Berinert: 500 units</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cinryze: 500 units (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Haegarda: 2000 units (1 ea); 3000 units (1 ea)</p></div>
<div class="block geq drugH1Div" id="F6764774"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16321852"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Berinert Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (per each): $4,605.52</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Cinryze Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (per each): $3,726.05</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Haegarda Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2000 unit (per each): $2,640.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3000 unit (per each): $3,961.08</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868982"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Berinert: 500 units, 1500 units</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cinryze: 500 units (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Haegarda: 2000 units (1 ea); 3000 units (1 ea)</p></div>
<div class="block accres drugH1Div" id="F11368727"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Assistance with procurement and reimbursement of Cinryze is available for health care providers and patients through the CINRYZE<i>Solutions</i> program (telephone: 1-877-945-1000) or at http://www.cinryze.com/Cinryze_Solutions/Default.aspx
                  </p></div>
<div class="block adm drugH1Div" id="F6764796"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Berinert (500 unit vial): Administer intravenously at ~4 mL/minute by a separate infusion line. Use a silicone-free syringe for administration.</p>
<p style="text-indent:-2em;margin-left:4em;">Berinert (1,500 unit vial) [Canadian product]: Administer intravenously by slow injection by a separate infusion line.</p>
<p style="text-indent:-2em;margin-left:4em;">Cinryze: Administer intravenously at 1 mL/minute (as a guideline, administer 1,000 units over 10 minutes and 500 units over 5 minutes). Use of a silicone-free syringe for administration is recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Haegarda: For SUBQ injection only in the abdominal area or other SUBQ injection sites. Rotate injection sites. Use a silicone-free syringe for administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Self-administration: Following patient training and instructions on self-administration, patient may self-administer treatment (Berinert) or prophylaxis (Cinryze, Haegarda) therapy. Epinephrine should be available during self-administration in the event of an acute, severe hypersensitivity reaction. Patient suffering from an acute laryngeal hereditary angioedema attack and self-administering should be informed to seek immediate medical attention following treatment (potential for airway obstruction to occur).</p></div>
<div class="block admp drugH1Div" id="F52614283"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral:</p>
<p style="text-indent:-2em;margin-left:2em;">IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Berinert: A silicone-free syringe is recommended for administration. Administer IV at recommended infusion rate: 4 mL/minute (200 units/minute); use within 8 hours of reconstitution; discard any unused product.</p>
<p style="text-indent:-2em;margin-left:4em;">Cinryze: A silicone-free syringe is recommended for administration. Administer IV at recommended infusion rate: 1 mL/minute; use within 3 hours of reconstitution; discard any unused product.</p>
<p style="text-indent:-2em;margin-left:4em;">Self-administration: Following patient or caregiver training and instructions on self-administration, patient or caregiver may self-administer treatment (Berinert) or prophylaxis (Cinryze) therapy. Epinephrine should be available during self-administration in the event of an acute, severe hypersensitivity reaction. Any patient suffering from an acute laryngeal hereditary angioedema attack and self-administering should be informed to seek immediate medical attention following treatment (potential for airway obstruction to occur).</p>
<p style="text-indent:-2em;margin-left:2em;">SUBQ: Haegarda: A silicone-free syringe is recommended for administration. Administer SUBQ in the abdominal area or other SUBQ injection sites. Rotate injection sites. Use within 8 hours of reconstitution; discard any unused product.</p>
<p style="text-indent:-2em;margin-left:4em;">Self-administration: Following patient training and instructions on self-administration, patient may self-administer prophylaxis therapy. Epinephrine should be available during self-administration in the event of an acute, severe hypersensitivity reaction.</p></div>
<div class="block use drugH1Div" id="F6764775"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hereditary angioedema:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Berinert: Treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) in adults and pediatric patients.</p>
<p style="text-indent:-2em;margin-left:4em;">Cinryze: Routine prophylaxis against angioedema attacks in adults, adolescents, and pediatric patients ≥6 years of age with HAE.</p>
<p style="text-indent:-2em;margin-left:4em;">Haegarda: Routine prophylaxis against angioedema attacks in adults and pediatric patients ≥6 years of age with HAE.</p></div>
<div class="block off-label drugH1Div" id="F57324724"><span class="drugH1">Use: Off-Label: Adult</span><p>Hereditary angioedema attacks, short-term prophylaxis; Hereditary angioedema attacks, treatment</p></div>
<div class="block cyt drugH1Div" id="F13298919"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6764785"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the thrombogenic effect of C1 inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May enhance the thrombogenic effect of C1 inhibitors.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F57941523"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Exogenous estrogen, including estrogen containing contraceptives, can precipitate hereditary angioedema (HAE) attacks. Although hormone therapy is generally avoided in persons with HAE, C1 inhibitor (human) prophylaxis may benefit patients who require hormone therapy to lessen the burden of illness in special circumstances, including those undergoing fertility treatments, feminizing hormone therapy, or to manage symptoms of menopause (US HAEA [Busse 2021]).</p></div>
<div class="block pri drugH1Div" id="F6764778"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">C1 esterase inhibitor is endogenous to human plasma.</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data are available following maternal administration of C1 inhibitor (human) for the prevention and treatment of hereditary angioedema (HAE) attacks during pregnancy; use has not been associated with adverse pregnancy outcomes (Baker 2013; Brooks 2020; Farkas 2007; Fox 2017; Garcia 2018; González-Quevedo 2016; Levy 2020; Martinez-Saguer 2010; Triggianese 2022).</p>
<p style="text-indent:0em;margin-top:2em;">C1 inhibitor (human) is preferred for the management of HAE during pregnancy and may be used for acute attacks, short-term prophylaxis, and long-term prophylaxis. Pre-procedural prophylaxis before uncomplicated natural delivery is not mandatory; however, C1 inhibitor (human) should be immediately available for on-demand use. Pre-procedural prophylaxis is recommended before labor and delivery when symptoms have been recurring frequently during the third trimester and the patient's history includes genital edema caused by mechanical trauma; during forceps delivery or vacuum extraction; before a caesarean section; before surgery or general anesthesia when intubation is required; and before interventions having a risk of attacks such as chorionic villus sampling, amniocentesis, and induced surgical abortion. Patients with HAE should be monitored closely during pregnancy and for at least 72 hours after delivery (US HAEA [Busse 2021]; WAO/EAACI [Maurer 2022]).</p></div>
<div class="block brc drugH1Div" id="F21099198"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if C1 inhibitor (human) is present in breast milk following maternal administration; however, C1 esterase inhibitor is endogenous to human plasma.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Lactation may increase the frequency of hereditary angioedema (HAE) attacks; patients with HAE should be monitored closely. C1 inhibitor (human) is a preferred agent for the management of HAE during lactation (US HAEA [Busse 2021]; WAO/EAACI [Maurer 2022]).</p></div>
<div class="block mop drugH1Div" id="F23907080"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs/symptoms of hypersensitivity reactions and thrombotic events.</p></div>
<div class="block pha drugH1Div" id="F6764789"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">C1 inhibitor, one of the serine proteinase inhibitors found in human blood, plays a role in regulating the complement and intrinsic coagulation (contact system) pathway, and is also involved in the fibrinolytic and kinin pathways. C1 inhibitor therapy in patients with C1 inhibitor deficiency, such as HAE, is believed to suppress contact system activation via inactivation of plasma kallikrein and factor XIIa, thus preventing bradykinin production. Unregulated bradykinin production is thought to contribute to the increased vascular permeability and angioedema observed in HAE.</p></div>
<div class="block phk drugH1Div" id="F6764790"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Cinryze: Increased plasma C1 inhibitor levels observed ~1 hour or less.</p>
<p style="text-indent:-2em;margin-left:2em;">Onset of symptom relief: Berinert: Median: 15 minutes per attack; Cinryze: Pediatric patients 6 to 17 years: Median: 30 minutes per attack; for the majority of patient unequivocal symptom relief reported within 1 hour (range: 15 to 135 minutes) (Lumry 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration of action: Time to complete resolution of hereditary angioedema (HAE) symptoms: Berinert: Median: 8.4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution:</p>
<p style="text-indent:-2em;margin-left:4em;">Berinert: V<sub>ss</sub>: Children and Adolescents (6 to 13 years, n=5): 0.02 L/kg (range: 0.017 to 0.026 L/kg); Adults: 0.018 L/kg (range: 0.011 to 0.028 L/kg).</p>
<p style="text-indent:-2em;margin-left:4em;">Haegarda: V<sub>d</sub>: Children ≥8 years, Adolescents, and Adults: 0.05 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Haegarda: Children ≥8 years, Adolescents, and Adults: 42.7%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Berinert:</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents (6 to 13 years, n=5): 22 hours (range: 20 to 24 hours).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults (following a single dose): 22 hours (range: 17 to 24 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">Cinryze: Adults: 56 hours (range: 11 to 108 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">Haegarda: Children ≥8 years, Adolescents, and Adults: 69 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Cinryze: ~4 hours; Haegarda: Children ≥8 years, Adolescents, and Adults: 59 hours.</p></div>
<div class="block phksp drugH1Div" id="F51774071"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Pediatric:</p>
<p style="text-indent:-2em;margin-left:4em;">Cinryze: Compared to adults, children 7 to 11 years of age showed a 30% higher mean AUC and C<sub>max</sub> at a 1,000 unit dose level.</p>
<p style="text-indent:-2em;margin-left:4em;">Haegarda: Compared to adults, children (8 to &lt;12 years) and adolescents (12 to &lt;18 years) showed a 11% and 10% higher weight-adjusted clearance, respectively.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F23672322"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Berinert | Cinryze</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Berinert hs | Berinert p | Cinryze</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Berinert</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Berinert | Cinryze</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Berinert</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Berinert | Cinryze</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Berinert | Cinryze</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Berinert | Cinryze</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Berinert | Berinert p | Cinryze</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Berinert | Cinryze</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Berinert | Berinertp c1 | Cinryze</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cinryze</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Berinert p | Cinryze</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Berinert | Cebitor | Cinryze</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Berinert | Cinryze | Esterasine</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Berinert | Cinryze</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Berinert</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Cinryze</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Berinert p</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cinryze</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Berinert | Cinryze</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Berinert | Berinert p</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Berinert</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Berinert p | Cinryze</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cinryze</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Berinert</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Berinert | Cinryze</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Berinert | Cinryze</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Berinert | Berinert p</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Berinert | Cinryze | Haegarda</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Berinert | Berinert p | Cinryze</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Berinert | Cinryze | Haegarda</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Berinert | Cinryze</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Berinert</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Berinert</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Berinert | Cinryze</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Berinert p</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Berinert p | Cetor | Cinryze</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Berinert | Cinryze</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-33980333">
<a name="33980333"></a>Ajewole O, Lanlokun M, Dimanche S, Craig T. Short-term prophylaxis for children and adolescents with hereditary angioedema. <i>Allergy Asthma Proc</i>. 2021;42(3):205-213. doi:10.2500/aap.2021.42.210006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/33980333/pubmed" id="33980333" target="_blank">33980333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23484892">
<a name="23484892"></a>Baker JW, Craig TJ, Riedl MA, et al. Nanofiltered C1 esterase inhibitor (human) for hereditary angioedema attacks in pregnant women. <i>Allergy Asthma Proc.</i> 2013;34(2):162-169. doi:10.2500/aap.2013.34.3645<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/23484892/pubmed" id="23484892" target="_blank">23484892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berinert.1">
<a name="Berinert.1"></a>Berinert (C1 esterase inhibitor [human]) [prescribing information]. Kankakee, IL: CSL Behring LLC; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berinert.2">
<a name="Berinert.2"></a>Berinert 500 (C1 esterase inhibitor [human]) [summary of product characteristics]. West Sussex, United Kingdom: CSL Behring UK Limited; January 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berinert.3">
<a name="Berinert.3"></a>Berinert 500/Berinert 1500 (C1 Esterase Inhibitor [Human]) [product monograph]. Ottawa, Ontario, Canada: CSL Behring Canada Inc; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32251736">
<a name="32251736"></a>Brooks JP, Radojicic C, Riedl MA, Newcomer SD, Banerji A, Hsu FI. Experience with intravenous plasma-derived C1-inhibitor in pregnant women with hereditary angioedema: a systematic literature review. <i>J Allergy Clin Immunol Pract.</i> 2020;8(6):1875-1880.e3. doi:10.1016/j.jaip.2020.03.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/32251736/pubmed" id="32251736" target="_blank">32251736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32898710">
<a name="32898710"></a>Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. <i>J Allergy Clin Immunol Pract</i>. 2021;9(1):132-150.e3. doi:10.1016/j.jaip.2020.08.046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/32898710/pubmed" id="32898710" target="_blank">32898710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22197274">
<a name="22197274"></a>Caballero T, Farkas H, Bouillet L, et al. International Consensus and Practical Guidelines on the Gynecologic and Obstetric Management of Female Patients With Hereditary Angioedema Caused by C1 Inhibitor Deficiency. <i>J Allergy Clin Immunol</i>. 2012;129(2):308-320.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/22197274/pubmed" id="22197274" target="_blank">22197274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cinryze.1">
<a name="Cinryze.1"></a>Cinryze (C1 esterase inhibitor [human]) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cinryze.2">
<a name="Cinryze.2"></a>Cinryze (C1 esterase inhibitor [human]) [European Medicines Agency summary of product characteristics]. Brussels, Belgium: Shire Services BVBA; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cinryze.3">
<a name="Cinryze.3"></a>Cinryze (C1 esterase inhibitor [human]) [summary of product characteristics]. Brussels, Belgium: Shire Services BVBA; May 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23282420">
<a name="23282420"></a>Craig T, Aygören-Pürsün E, Bork K, et al. WAO guideline for the management of hereditary angioedema. <i>World Allergy Organ J</i>. 2012;5(12):182-199. doi:10.1097/WOX.0b013e318279affa<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/23282420/pubmed" id="23282420" target="_blank">23282420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19767078">
<a name="19767078"></a>Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks.<i> J Allergy Clin Immunol</i>. 2009;124(4):801-808. doi:10.1016/j.jaci.2009.07.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/19767078/pubmed" id="19767078" target="_blank">19767078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17761272">
<a name="17761272"></a>Farkas H, Jakab L, Temesszentandrási G, et al. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. <i>J Allergy Clin Immunol.</i> 2007;120(4):941-947. doi:10.1016/j.jaci.2007.06.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/17761272/pubmed" id="17761272" target="_blank">17761272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27503784">
<a name="27503784"></a>Farkas H, Martinez-Saguer I, Bork K, et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. <i>Allergy</i>. 2017;72(2):300-313. doi:10.1111/all.13001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/27503784/pubmed" id="27503784" target="_blank">27503784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28441992">
<a name="28441992"></a>Fox J, Vegh AB, Martinez-Saguer I, et al. Safety of a C1-inhibitor concentrate in pregnant women with hereditary angioedema. <i>Allergy Asthma Proc</i>. 2017;38(3):216-221. doi:10.2500/aap.2017.38.4038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/28441992/pubmed" id="28441992" target="_blank">28441992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29439936">
<a name="29439936"></a>Garcia JFB, Takejima P, Veronez CL, et al. Use of pdC1-INH concentrate for long-term prophylaxis during pregnancy in hereditary angioedema with normal C1-INH. <i>J Allergy Clin Immunol Pract.</i> 2018;6(4):1406-1408. doi:10.1016/j.jaip.2017.12.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/29439936/pubmed" id="29439936" target="_blank">29439936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27326983">
<a name="27326983"></a>González-Quevedo T, Larco JI, Marcos C, et al. Management of pregnancy and delivery in patients with hereditary angioedema due to C1 inhibitor deficiency. <i>J Investig Allergol Clin Immunol.</i> 2016;26(3):161-167. doi:10.18176/jiaci.0037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/27326983/pubmed" id="27326983" target="_blank">27326983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Haegarda.1">
<a name="Haegarda.1"></a>Haegarda (C1 Esterase Inhibitor [Human]) [prescribing information]. Kankakee, IL: CSL Behring LLC; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Haegarda.2">
<a name="Haegarda.2"></a>Haegarda (C1 Esterase Inhibitor [Human]) [prescribing information]. Kankakee, IL: CSL Behring LLC; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Haegarda.3">
<a name="Haegarda.3"></a>Haegarda (C1 Esterase Inhibitor [Human]) [product monograph]. Ottawa, Ontario, Canada: CSL Behring Canada Inc; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17653743">
<a name="17653743"></a>Hermans C. Successful Management With C1-Inhibitor Concentrate of Hereditary Angioedema Attacks During Two Successive Pregnancies: A Case Report. <i>Arch Gynecol Obstet</i>. 2007;276(3):271-276.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/17653743/pubmed" id="17653743" target="_blank">17653743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32042283">
<a name="32042283"></a>Levy DS, Farkas H, Riedl MA, et al. Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial. <i>Allergy Asthma Clin Immunol.</i> 2020;16:8. doi:10.1186/s13223-020-0409-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/32042283/pubmed" id="32042283" target="_blank">32042283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28328347">
<a name="28328347"></a>Longhurst H, Cicardi M, Craig T, et al; COMPACT Investigators. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. <i>N Engl J Med</i>. 2017;376(12):1131-1140. doi:10.1056/NEJMoa1613627<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/28328347/pubmed" id="28328347" target="_blank">28328347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23312695">
<a name="23312695"></a>Lumry W, Manning ME, Hurewitz DS, et al. Nanofiltered C1-Esterase Inhibitor for the Acute Management and Prevention of Hereditary Angioedema Attacks Due to C1-Inhibitor Deficiency in Children. <i>J Pediatr</i>. 2013;162(5):1017-1022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/23312695/pubmed" id="23312695" target="_blank">23312695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20471627">
<a name="20471627"></a>Martinez-Saguer I, Rusicke E, Aygören-Pürsün E, Heller C, Klingebiel T, Kreuz W. Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. <i>Am J Obstet Gynecol</i>. 2010;203(2):131.e1-131.e7. doi:10.1016/j.ajog.2010.03.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/20471627/pubmed" id="20471627" target="_blank">20471627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29318628">
<a name="29318628"></a>Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema: the 2017 revision and update [published online January 10, 2018]. <i>Allergy</i>. doi:10.1111/all.13384<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/29318628/pubmed" id="29318628" target="_blank">29318628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35497649">
<a name="35497649"></a>Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema - the 2021 revision and update.<i> World Allergy Organ J</i>. 2022;15(3):100627. doi:10.1016/j.waojou.2022.100627<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/35497649/pubmed" id="35497649" target="_blank">35497649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to the manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27286778">
<a name="27286778"></a>Riedl MA, Bygum A, Lumry W, et al; Berinert Registry investigators. Safety and usage of C1-inhibitor in hereditary angioedema: Berinert registry data. <i>J Allergy Clin Immunol Pract</i>. 2016;4(5):963-971. doi:10.1016/j.jaip.2016.04.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/27286778/pubmed" id="27286778" target="_blank">27286778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28781749">
<a name="28781749"></a>Sabharwal G, Craig T. Pediatric hereditary angioedema: an update. <i>F1000Res</i>. 2017;6:F1000 Faculty Rev-1205. doi:10.12688/f1000research.11320.1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/28781749/pubmed" id="28781749" target="_blank">28781749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36186797">
<a name="36186797"></a>Triggianese P, Senter R, Petraroli A, et al. Pregnancy in women with Hereditary Angioedema due to C1-inhibitor deficiency: results from the ITACA cohort study on outcome of mothers and children with in utero exposure to plasma-derived C1-inhibitor. <i>Front Med (Lausanne).</i> 2022;9:930403. doi:10.3389/fmed.2022.930403<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/36186797/pubmed" id="36186797" target="_blank">36186797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21195947">
<a name="21195947"></a>Wasserman RL, Levy RJ, Bewtra AK, et al. Prospective study of C1 esterase inhibitor in the treatment of successive acute abdominal and facial hereditary angioedema attacks. <i>Ann Allergy Asthma Immunol</i>. 2011;106(1):62-68. doi:10.1016/j.anai.2010.10.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/21195947/pubmed" id="21195947" target="_blank">21195947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26304015">
<a name="26304015"></a>Zanichelli A, Mansi M, Azin GM, et al. Efficacy of on-demand treatment in reducing morbidity in patients with hereditary angioedema due to C1 inhibitor deficiency. <i>Allergy</i>. 2015;70(12):1553-1558. doi:10.1111/all.12731<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/26304015/pubmed" id="26304015" target="_blank">26304015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zuraw.1">
<a name="Zuraw.1"></a>Zuraw B, Farkas H. Hereditary angioedema: acute treatment of angioedema attacks. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 29, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20818886">
<a name="20818886"></a>Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. <i>N Engl J Med</i>. 2010;363(6):513-522. doi:10.1056/NEJMoa0805538<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/c1-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/20818886/pubmed" id="20818886" target="_blank">20818886</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8998 Version 231.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
